

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors

Supplemental Table 1B

	No.	GvHD before EBV-CTL transfer	details of GvHD before EBV-CTL transfer	GvHD after EBV-CTL transfer	details of GvHD after EBV-CTL transfer	reason for GvHD after EBV-CTL transfer	transfer of unspecific DLI	clinical response	EBV-PCR (blood) after EBV-CTL transfer	follow-up (months)	patient alive/deceased	reason for death
HSCT patient: EBV-CTL from SCD (Ia)	16	yes	cerebral vasculitis (imaging)	none	-	-	no	CR	negative**	77	alive	-
	17	none	-	yes	skin 1°, bowel 2°	n.a.	n.a.	CR	positive but not quantifiable	31	alive	-
	18	yes	acute bowel 4°, chronic articulations 1°	none	-	-	no	early death (n.a.)			deceased	multiorgan failure, EBV encephalitis, septic shock, GvHD
	19	yes	skin 2°, bowel 1°	none	-	-	no	CR	negative	11	deceased	adenovirus-mengoencephalitis + bacterial sepsis
	20	none	-	yes	skin moderate, bowel mild	reduction of everolimus	no	CR	negative	51	alive	-
	21	none	-	none	-	-	no	CR	negative**	52	alive	-
	22	yes	bowel 1°	chronic	bowel chronic (limited disease, NIH-SS mild)	unknown (association with EBV possible)	no	CR	negative	6	deceased	adenovirus encephalitis, pneumonia, liver failure
	23	none	-	yes	skin 3°, oral mucosa 3°, liver 3°	association with DLI and pembrolizumab	yes	CR	positive (stable)	6	deceased	influenza, sepsis
	24	none	-	none	-	-	no	CR	positive but not quantifiable	44	alive	-
	25	none	-	none	-	-	no	PD	positive (stable)	1	deceased	progression of PTLD
	26	none	-	none	-	-	yes	CR	negative	40	alive	-
HSCT patient: EBV-CTL from TPD (Ib)	1	yes	skin 3°; resolved before EBV-CTL transfer	none	-	-	no	CR	negative	71	alive	-
	2	none	-	(none)	-	-	no	early death (n.a.)			deceased	progression of EBV-associated necrotizing encephalitis
	3	yes	skin 3°; resolved before EBV-CTL transfer	none	-	-	no	CR	negative	71	alive	-
	4	yes	skin 2°, liver 1°, bowel 2°, oral mucosa 2°	yes, chronic	skin 2°, liver 1°, bowel 2°, eyes 1°	unknown (association with EBV possible)	no***	n.a.	negative**	3	deceased	chronic GvHD
	5	yes	skin 2°	(none)	-	-	no	early death (n.a.)			deceased	multiorgan failure (presumably EBV-associated)
	6	yes	bowel 1°	yes, new symptoms	skin 3°	association with DLI (and sorafenib)	yes	CR	negative	5	deceased	progression of AML
	7	yes	skin 2°, bowel 3°	no new symptoms	no new symptoms	-	no	CR	negative (liquor: low positive)	38	deceased	secondary malignoma (glioblastoma multiforme)
	8	none	-	none	-	-	no	PD	positive (decline)	2	deceased	progression of PTLD
	9	yes	skin 2°	none	-	-	no	PD	negative	2	deceased	multiorgan failure
	10	yes	skin 3°, bowel 3°	(none)	-	-	no	early death (n.a.)			deceased	progression of PTLD and AML
	11	none	-	none	-	-	no	CR	negative	11	alive	-
	12	yes	skin 1°	none	-	-	no	CR	negative	42	alive	-
	13	yes	skin chronic (limited disease, NIH-SS moderate)	none	-	-	no	SD	positive (decline)	1	deceased	atypic pneumonia
	14	yes	skin 3°	no new symptoms	-	-	no	CR	negative	48	alive	-
	15	yes	skin 2°, bowel 1°	yes, new symptoms	skin 4°, bowel 2°, liver 3°	association with nivolumab	no	PR, finally PD	positive (increase)	10	deceased	progression of PTLD, severe GvHD following nivolumab, septic shock
SOT patient: EBV-CTL from TPD (II)	27	none	-	none	-	-	-	SD****	negative	69	alive	-
	28	none	-	none	-	-	-	CR before transfer of EBV-CTL	negative**	77	alive	-
	29	none	-	none	-	-	-	CR before transfer of EBV-CTL	negative**	61	alive	-
	30	none	-	none	-	-	-	CR	negative**	58	alive	-
	31	none	-	none	-	-	-	CR	positive (decline)	27	alive	-
no Tx; EBV-CTL from TPD (III)	32	-	-	none	-	-	-	PD	positive (decline)	3	deceased	progression of EBV-associated lymphoproliferation
	33	-	-	none	-	-	-	SD	negative after SCT*	64	alive	-
	34	-	-	none	-	-	-	CR after SCT	negative after SCT	22	alive	-
	35	-	-	none	-	-	-	PR****	negative**	40	alive	-
	36	-	-	none	-	-	-	CR	positive (decline)	44	alive	-
EBV-CTL not used	37	-	-	-	-	-	-	-	-	-	deceased	multiorgan failure, uncontrolled EBV reactivation and lymphoproliferation
	38	-	-	-	-	-	-	-	-	-	deceased	aspergillosis, progression of PTLD
	39	-	-	-	-	-	-	-	-	-	alive	-
	40	-	-	-	-	-	-	-	-	-	alive	-

patients with two EBV-CTL manufacturing processes: No. 1 = No. 3; No. 24 = No. 36; No. 33 = No. 40

*patient No. 33: increasing EBV load despite EBV-CTL transfer, CR after HSCT without further EBV treatment

** EBV-PCR negative before transfer of EBV-CTL

***patient No. 4: no DLI but transfer of CMV-CTL 3 months before transfer of EBV-CTL

****patient No. 27 and 35: clinical response SD/PR but complete metabolic response (PET)